Brief: Cipla's Manufacturing Facility In Goa Undergoes US FDA Inspection
17/04/2026 12:32
April 17 (Reuters) - Cipla Ltd CIPL.NS: CIPLA - USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN GOA, INDIA CIPLA - USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN GOA, INDIA CIPLA - USFDA CONDUCTS INSPECTION AT CIPLA GOA FACILITY FROM APRIL 6-17, 2026 CIPLA - RECEIVES TWO INSPECTIONAL OBSERVATIONS IN FORM 483 Source text: ID:nBSE5VLYW0 Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate